Pre-Open Stock Movers 10/11: (KMPH) (SUPN) (TWLO) Higher; (RCII) (ILMN) (LITE) Lower (more...)
- S&P 500 edges down on virus woes, slowing economy
- 'Becoming JP Morgan of the Future': Square (SQ) Dips on Deal to Acquire BNPL Afterpay For $29B in Stock, Benefits Outweigh High Price Says Analyst
- Oil falls over 3% on concerns over demand and OPEC supply boost
- ON Semiconductor (ON) Surges on Strong Q2 Results and Q3 Outlook
- Dollar wavers on dovish Fed tone, mixed economic outlook
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Today's Pre-Open Stock Movers
Rent-A-Center, Inc. (Nasdaq: RCII) 32% LOWER; warns for Q3, sees between $0.05 and $0.15 versus the consensus of $0.39.
Illumina, Inc. (Nasdaq: ILMN) 23.5% LOWER; announced estimated third quarter revenue of approximately $607 million, a 10% increase compared to $550 million in the third quarter of 2015. This unaudited estimate, based on management's preliminary financial analysis, is lower than the third quarter revenue guidance of $625 million to $630 million. (Note: The Street sees revenue of $628.1 million.)
KemPharm, Inc. (Nasdaq: KMPH) 20.9% HIGHER; announced that its Investigational New Drug (IND) application for KP415 has been accepted by the U.S. Food and Drug Administration (FDA). KP415, KemPharms co-lead product candidate, is an extended release (ER) d-threo-methylphenidate (d-MPH) prodrug for the treatment of attention deficit hyperactivity disorder (ADHD). KemPharm expects to commence and complete proof of concept human trials prior to the end of 2016, with additional human clinical trials initiating during the first half of 2017.
Horizon Pharma (NASDAQ: HZNP) 7.4% LOWER; disclosed that it sees 2016 adjusted EBITDA in the range of $450 to $460 million (prior range was $495 to $510 million).
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) 7% HIGHER; announced final results from the pivotal Phase 3 NAPOLI-1 study validating the use of ONIVYDE (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin, which represents a new standard of care for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) following treatment with gemcitabine-based therapy. The final NAPOLI-1 results were presented in a poster discussion session and a separate analysis of NAPOLI-1 safety-over-time data was presented in a poster session at the European Society for Medical Oncology 2016 Congress in Copenhagen.
Lipocine Inc (NASDAQ: LPCN) 6.3% HIGHER; Canaccord Genuity maintained a Buy rating and raised its price target to $15.00 (from $6.00).
Pacific Bio (Nasdaq: PACB) 5.6% LOWER; down on ILMN warning
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) 5.3% HIGHER; announced positive topline results from its Phase IIb dose-ranging clinical trial of SPN-812 in children for the treatment of attention deficit hyperactivity disorder (ADHD).
Organovo Holdings, Inc. (Nasdaq: ONVO) 4.6% HIGHER; reported preliminary unaudited revenue and net cash utilization results for the fiscal second quarter of 2017 and updated its full-year fiscal 2017 outlook. The Company expects to release full fiscal second-quarter financial results on November 3, 2016.
Aaron's, Inc. (NYSE: AAN) 4.5% LOWER; down on RCII warning
Twilio (NYSE: TWLO) 4.5% HIGHER; Total revenue of $70.25 million to $71.25 million, compared to total revenue of $44.3 million in the three months ended September 30, 2015. (NOTE: The Street sees revenue of $64.4 million.)
Momenta Pharmaceuticals (NASDAQ: MNTA) 4% HIGHER; Barclays upgraded from Equalweight to Overweight with a price target of $19.00 (from $13.00).
Alcoa (NYSE: AA) 4% LOWER; reported Q3 EPS of $0.32, $0.02 worse than the analyst estimate of $0.34. Revenue for the quarter came in at $5.21 billion versus the consensus estimate of $5.33 billion.
Auris Medical Holding AG (NASDAQ: EARS) 2.5% HIGHER; announced that it will provide an update on the KeyzilenTM development program tomorrow, Tuesday, October 11, 2016. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the program update for KeyzilenTM, which is in Phase 3 development for the treatment of acute inner ear tinnitus.
Lending Club (NYSE: LC) 2.3% LOWER; Wedbush initiated coverage with an Underperform rating and a price target of $3.75.
Twitter, Inc. (NYSE: TWTR) 2.3% HIGHER; Evercore ISI upgraded from Sell to Hold and maintains a price target of $17.00. Positive comments Deutsche Bank.
Finisar (NASDAQ: FNSR) 2.2% HIGHER; Goldman Sachs upgraded from Neutral to Buy with a price target of $39.00 (from $24.00
Thermo Fisher (NYSE: TMO) 2% LOWER; down on ILMN warning
Chatham Lodging Trust (NYSE: CLDT) 2% LOWER; sees Q3 AFFO of $0.70-$0.70 versus prior outlook of $0.72-$0.75 and the consensus of $0.74.
Altria Group (NYSE: MO) 1.2% HIGHER; Updates on FY16 Outlook; Adds $1B to Stock Buyback Plan (BUD)
Agilent (NYSE: A) 1% LOWER; down on ILMN warning
Qiagen NV (NASDAQ: QGEN) 0.3% LOWER; down on ILMN warning
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 08/02: (XCUR) (DLPN) (AUTL) Higher; (PH) (SQ) Lower (more...)
- Univar (UNVR) Tops Q2 EPS by 10c; Raises Adj-EBITDA Outlook
- Kredivo Announces Plans to Become Publicly Traded Company via Merger with VPC Impact Acquisition Holdings II (VPCB)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesDeutsche Bank, Goldman Sachs, Barclays, Twitter, Stock Buyback, Earnings, Canaccord Genuity, Pre-Open Losers, Pre-Open Winners, Pre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!